Biomea Fusion, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Financial statements are unaudited. Biomea Fusion is a clinical-stage biotechnology company developing covalent small-molecule medicines; it has no approved products and has generated no revenue.
Financial performance and liquidity
| Metric | Q2 2022 | Six months 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $12.6 million | $23.9 million | $5.2 million; $9.0 million |
| General and administrative expense | $4.9 million | $9.9 million | $3.2 million; $5.3 million |
| Total operating expenses | $17.5 million | $33.9 million | $8.4 million; $14.3 million |
| Net loss | $17.3 million | $33.6 million | $8.4 million; $14.3 million |
| Basic and diluted net loss per share | $0.59 | $1.15 | $0.33; $0.77 |
- At June 30, 2022, cash and cash equivalents were $148.5 million, investments were $1.3 million, and restricted cash was $0.4 million; together, these totaled approximately $150.2 million. Management said these resources were expected to fund operations for at least one year beyond the financial statement issuance date.
- Operating cash used was $25.4 million in the first half, versus $10.6 million in the first half of 2021. Investing activities provided $27.8 million, primarily from investment maturities; financing provided $0.3 million. Cash, cash equivalents, and restricted cash increased $2.7 million.
- Total assets were $161.7 million and stockholders’ equity was $150.4 million. Total liabilities were $11.3 million, including $2.6 million in operating lease liabilities. The company reported no interest-bearing liabilities.
- Accumulated deficit was $83.4 million. No product-sales margins are applicable because the company has no revenue.
Changes versus prior periods
- Q2 operating expenses rose $9.0 million year over year; first-half expenses rose $19.6 million. Management attributed the increases primarily to advancing BMF-219 development and higher personnel costs, with additional public-company and professional-service costs in G&A.
- First-half net loss increased to $33.6 million from $14.3 million. Operating cash use also increased, while the 2021 period included $152.8 million of net IPO proceeds; there were no IPO proceeds in 2022.
- Cash and cash equivalents increased from $145.7 million at December 31, 2021 to $148.5 million at June 30, 2022, while investments declined from $29.7 million to $1.3 million, largely reflecting investment maturities and reallocation into cash.
Outlook, commentary and risks
- Management expects operating losses and expenses to rise as clinical and preclinical programs advance. The company anticipates needing substantial additional capital; future financing may be unavailable or dilutive, and could require program delays, reductions, or licensing of product rights.
- BMF-219’s Phase 1 COVALENT-101 trial had begun dosing leukemia patients in January 2022, and the first patient in the multiple myeloma cohort was dosed in June. The filing describes preclinical findings across cancer and diabetes models; these findings do not establish clinical benefit in people.
- Subject to IND submission and clearance, the company planned to initiate a Phase 1/2 study of BMF-219 in KRAS-mutant lung, colorectal, and pancreatic cancers in Q4 2022, and a Phase 1/2 diabetes study in the second half of 2022. It also expected to update investors on a third development candidate during 2022. These are plans, not assurances.
- BMF-500, a potential oral covalent FLT3 inhibitor, was selected as the company’s second development candidate in May 2022.
- Key risks include early-stage clinical uncertainty, possible safety or efficacy failures, regulatory and enrollment delays, dependence on third-party manufacturers and research organizations, competition, and COVID-19 or broader economic and supply-chain disruption. The company reported no material legal proceedings and no subsequent events.
Important facts for investors to verify
- Whether BMF-219 clinical data support the preclinical claims, and whether safety, enrollment, or trial timelines change.
- Whether the planned KRAS-cancer and diabetes trials received IND clearance and began on the stated timelines.
- How actual cash burn and development spending compare with the stated runway estimate, and when additional financing may be needed.
- Progress of BMF-500 and the third candidate, including IND-enabling work, manufacturing readiness, and any revised development plans.
- Whether COVID-19, supply constraints, inflation, or reliance on third parties materially affect trial execution or costs.